Compass’ Psychedelic Shows Durability In Spades as Path to FDA Clears

Psilocybin-based therapy COMP360 from Compass Pathways targets FDA approval for treatment-resistant depression, with durability of effect framed as the key factor. New late-stage trial readouts for COMP006 (Phase 3) and COMP005 (Phase 3) report sustained improvements on the MADRS scale, including durability data through week 26. Compass emphasizes that the therapy maintained durability of effect at least through week 26 after one or two doses, and analysts highlight the dataset derisking potential for approval. Safety is presented as consistent with prior studies, though a small number of suicidal ideation events were noted at the 25 mg dose. Compass is preparing for a rolling NDA submission, and executives contrast the dosing durability strategy against esketamine (Spravato), which typically requires more frequent dosing to maintain durability.